0000000000454765

AUTHOR

Rudolf M. Huber

showing 3 related works from this author

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

2019

A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has ‘aggressive disease’, as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung NeoplasmsTime FactorsBevacizumabmedicine.medical_treatmentDocetaxelAntibodies Monoclonal HumanizedDisease-Free SurvivalRamucirumab03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerLungChemotherapybusiness.industryPatient SelectionAntibodies MonoclonalGeneral Medicinemedicine.diseaserespiratory tract diseasesBevacizumab030104 developmental biologyOncologychemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionAdenocarcinomaNintedanibNivolumabbusinessmedicine.drugFuture oncology (London, England)
researchProduct

Telomere Length in Circulating Leukocytes is Associated with Lung Function and Disease

2014

Several clinical studies suggest the involvement of premature ageing processes in chronic obstructive pulmonary disease (COPD). Using an epidemiological approach, we studied whether accelerated ageing indicated by telomere length, a marker of biological age, is associated with COPD and asthma, and whether intrinsic age-related processes contribute to the interindividual variability of lung function. Our meta-analysis of 14 studies included 934 COPD cases with 15 846 controls defined according to the Global Lungs Initiative (GLI) criteria (or 1189 COPD cases according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria), 2834 asthma cases with 28 195 controls, and s…

Lung DiseasesMalePulmonary and Respiratory MedicineSpirometryNetherlands Twin Register (NTR)Vital capacityVital Capacityennenaikainen vanheneminenDiseaseCohort StudiesPathogenesisPulmonary Disease Chronic ObstructiveTelomere HomeostasisSDG 3 - Good Health and Well-beingForced Expiratory VolumeastmaLeukocytes/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_HumansCOPDMedicinekeuhkoahtaumatautiAgedAsthmatelomeeriCOPDmedicine.diagnostic_testpremature agingbusiness.industrySmokingCase-control studyta3141Middle AgedTelomerespirometriamedicine.diseaseAsthmabiologinen ikäbiological age3. Good healthrespiratory tract diseasesEuropeSpirometryCase-Control StudiesImmunologyRegression Analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalebusinessEuropean Respiratory Journal
researchProduct

Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.

2007

Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40…

medicine.medical_specialtyLung Neoplasmsmedicine.drug_classAdministration OralPharmacologyVinorelbineVinblastineRoute of administrationchemistry.chemical_compoundOral administrationCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsMedicineAntiemeticHumansPharmacology (medical)Randomized Controlled Trials as Topicbusiness.industryCombination chemotherapyVinorelbineAntineoplastic Agents PhytogenicCombined Modality TherapyGemcitabineCarboplatinBioavailabilitySurgerychemistryOral vinorelbine small cell lung cancer.businessmedicine.drugDrugs
researchProduct